Health Care [ 4/12 ] | Pharmaceuticals [ 9/75 ]
NASDAQ | Common Stock
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer.
In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer.
It has collaborations with Pfizer Inc., Genentech, Inc., F.
Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG.
The company was founded in 2013 and is based in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 2, 26 | -1.10 Decreased by -74.60% | -0.50 Decreased by -122.00% |
| Oct 28, 25 | -0.48 Increased by +29.41% | -0.76 Increased by +36.84% |
| Aug 6, 25 | -0.84 Decreased by -71.43% | -0.89 Increased by +5.62% |
| May 1, 25 | 1.14 Increased by +217.53% | -0.97 Increased by +217.53% |
| Feb 11, 25 | -0.63 Increased by +75.10% | -0.96 Increased by +34.37% |
| Oct 30, 24 | -0.68 Increased by +42.37% | -0.87 Increased by +21.84% |
| Jul 30, 24 | -0.49 Increased by +60.80% | -0.86 Increased by +43.02% |
| May 7, 24 | -0.97 Increased by +37.01% | -1.42 Increased by +31.69% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 9.50 M Decreased by -83.95% | -67.40 M Decreased by -49.45% | Decreased by -709.47% Decreased by -831.28% |
| Sep 30, 25 | 41.90 M Decreased by -59.08% | -35.10 M Increased by +28.66% | Decreased by -83.77% Decreased by -74.35% |
| Jun 30, 25 | 22.40 M Decreased by -70.72% | -61.20 M Decreased by -73.86% | Decreased by -273.21% Decreased by -493.78% |
| Mar 31, 25 | 188.80 M Increased by +646.25% | 82.90 M Increased by +219.45% | Increased by +43.91% Increased by +116.01% |
| Dec 31, 24 | 59.20 M Increased by +237.35% | -45.10 M Increased by +70.87% | Decreased by -76.18% Decreased by -121.21% |
| Sep 30, 24 | 102.40 M Increased by +195.95% | -49.20 M Increased by +23.13% | Decreased by -48.05% Increased by +74.02% |
| Jun 30, 24 | 76.50 M Increased by +40.37% | -35.20 M Increased by +47.15% | Decreased by -46.01% Increased by +62.35% |
| Mar 31, 24 | 25.30 M Decreased by -22.15% | -69.40 M Increased by +15.26% | Decreased by -274.31% Decreased by -8.85% |